Will Healy

Will Healy

InvestorPlace Contributor

Will Healy is a freelance financial writer. He had a lifelong interest in the stock market, trading equities since the dot-com boom. Will pursued his passion for writing after working in the corporate world as both an analyst and an insurance sales professional. He likes to approach the market by focusing on deep value, dividends, and speculation.

Will’s writing has focused on stock analysis, as well as real estate, insurance, personal finance, macroeconomics, and politics. Along with InvestorPlace, his work has appeared on numerous sites, including Seeking Alpha, Yahoo! Finance, MSN Money, Kiplinger Tax Letter, and GOBankingRates. He holds both a B.S. in Journalism and an MBA in finance and strategy.

Recent Articles

Why Sprint Stock Should Be Avoided

By Will Healy, InvestorPlace Contributor

S stock shot higher after the government said that it was investigating Sprint's proposed merger. But the stock's risk/reward ratio is definitely negative.

Will Wall Street Care If Dropbox Beats Earnings?

By Will Healy, InvestorPlace Contributor

Dropbox releases its second earnings report in history, and analysts search for information to break DBX stock out of its trading range.

4 Russian Stocks to Buy With Low Valuations and High Dividends

By Will Healy, InvestorPlace Contributor

Investors often don't hear a lot about which Russian stocks to buy. But despite the uncertainty surrounding Russia sanctions, the country boasts some of the highest yields and lowest valuations of any market.

Despite Surge, DISH Stock Will Continue to Serve up Falling Profits

By Will Healy, InvestorPlace Contributor

DISH stock may have beaten earnings and revenue estimates, but no prospects exist to reverse the coming trend of falling profits.

Cannabis Should Still Spread Miracle-Gro on Scotts Stock

By Will Healy, InvestorPlace Contributor

SMG stock should continue to grow despite revenue miss, a bad quarter for marijuana, and the CEO's rant on the conference call.

Avoid Treating Biogen Like a Speculative Drug Stock

By Will Healy, InvestorPlace Contributor

BIIB stock rose and then fell following a successful Phase 2 trial, but success in getting drugs to market will determine the performance of Biogen stock in the end.

Avoid Gildan Stock – Despite Its Post-Earnings Surge

By Will Healy, InvestorPlace Contributor

GIL stock surged higher following an earnings beat, but the lack of a moat and a steady, but average performance leaves little reason to buy GIL stock.

4 High-Growth Solar Stocks Investors Should Watch

By Will Healy, InvestorPlace Contributor

These four solar stocks offer investors high growth and low multiples. Here's what you need to know about each.

Proposed Takeover Will Overshadow Forest City Earnings

By Will Healy, InvestorPlace Contributor

As Forest City goes into earnings, the proposed takeover by Brookfield and the corresponding legal challenges will overshadow the report. Here's what FCE.A stock investors should expect.

Why There’s Still Plenty of Hope for Lumber Liquidators Stock

By Will Healy, InvestorPlace Contributor

LL stock saw a massive drop on higher revenues and lower earnings, but Lumber Liquidators remains on track for high growth.

Load More